Pharmac has finalised a new supply contract with Pfizer to maintain funding for the Comirnaty COVID-19 vaccine.
This means that Comirnaty will continue to be the primary funded vaccine in New Zealand from 1 February 2026 until at least 30 September 2027.
There is also a possibility of extending the agreement until 2029.
“We’re pleased to confirm ongoing access to Comirnaty for New Zealanders,” Director Pharmaceuticals Adrienne Martin said.
The vaccine will remain available in various dosages suitable for infants, children, and adults. A new prefilled syringe designed for adults will also be launched, simplifying vaccine administration for healthcare professionals.
“The introduction of prefilled syringes will help streamline the vaccination process and support our health workforce,” Martin added.
Pharmac has modified its proposal based on input from clinicians and the public.
“In June, we invited people to share their views and received nearly 2,100 responses. We’re grateful to everyone who took the time to contribute – your insights help shape our decisions.”
During consultation, Pharmac received a broad spectrum of opinions about the COVID-19 vaccine, including both support and opposition, and has shared these views with relevant agencies like the Ministry of Health.
The Comirnaty COVID-19 vaccine, funded by Pharmac, has been approved by Medsafe for meeting safety and effectiveness standards both in New Zealand and internationally.
Some individuals favoured securing a future vaccine supply and the introduction of prefilled syringes. Others called for private access for those not currently eligible.
Some emphasised the importance of updated vaccines targeting variants or combination formulations.
Opinions on eligibility differed; some supported expanding access for children under 12, while others favoured a more focused approach. In response, Pharmac has implemented key changes to ensure that those most in need of protection have greater access.
Children under 12 who are severely immunocompromised or at high risk of serious illness will now qualify for additional doses every 6 or 12 months, respectively.
Those aged 12–29 who are severely immunocompromised or at high risk of serious illness will have access to updated vaccines every 6 months.